Trump installs sweeping new tariffs, but pharma dodges blow

The president will impose a baseline 10% tariff on all countries, as well as higher levies on certain nations. Pharmaceutical goods appear to be exempt, at least for now.

By Philip Neuffer • Updated April 3, 2025

J&J boosts US manufacturing as big pharma reshores

Following big announcements from Lilly and Merck, J&J is pledging $55 billion over the next four years to open new plants.

By Jonathan Gardner • March 21, 2025

NGS is changing GxP compliance. Will you adapt?

Discover NGS for GxP compliance with full audit trails, operational control and robust data security.

By QIAGEN Digital insights • March 17, 2025

Viking inks CordenPharma deal to boost obesity drug supply

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched weight loss treatment.

By Jonathan Gardner • March 11, 2025

Merck opens $1B vaccine plant in North Carolina

Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S.

By Delilah Alvarado • March 11, 2025

SynWeave™: Revolutionizing biopharma manufacturing by improving titer, timelines and manufacturability

Enhancing manufacturability is crucial for reducing the risks associated with scaling production.

March 10, 2025

Lilly CEO wields manufacturing plans to push pharma-friendly policies

While announcing billions of dollars in new U.S. investments, David Ricks called for an extension of 2017 tax cuts and changes to Medicare's drug negotiation program.

By Ned Pagliarulo • Feb. 26, 2025

Lilly expands US manufacturing build-out with $50B target

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry to reshore drug production.

By Ned Pagliarulo • Feb. 26, 2025

How Trump’s trade fight could impact the medical device industry

Relocating manufacturing would require substantial capital investment, but the timespan for the president’s new tariffs is unclear, supply chain experts said.

By Susan Kelly • Feb. 12, 2025

Tariffs raise concern among generic drugmakers, as advocacy groups seek exemptions

“There is not a single member of AAM who has not raised concerns about the tariff situation,” said the CEO of the generic drug lobby Association for Accessible Medicines.

By Kelly Bilodeau • Feb. 7, 2025

Zepbound, Mounjaro shortages are resolved, FDA confirms

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.

By Ned Pagliarulo • Dec. 19, 2024

Novo Holdings’ purchase of Catalent set to close after regulators’ green light

The $16.5 billion take-private deal can now be completed, along with Novo Nordisk’s related acquisition of three Catalent drug manufacturing plants.

By Ned Pagliarulo • Dec. 16, 2024

Lilly adds to obesity drug production push with $3B investment

The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana and will help make more injectable drugs like fast-selling Zepbound.

By Jonathan Gardner • Dec. 6, 2024

What might a Trump administration mean for the Biosecure Act?

Analysts see Trump’s victory raising the high-profile legislation’s chances of becoming law. But the realities of a lame duck Congress may cause its timeline for passage to slip back.

By Amy Baxter • Nov. 20, 2024

Novo sees Wegovy sales rise as supply constraints ease

Third quarter sales of Novo’s in-demand obesity drug totaled $2.5 billion, roughly 81% higher than the same period in 2023 and nearly doubling the total for Lilly’s Zepbound.

By Jonathan Gardner • Nov. 6, 2024

Novo takes big step toward ending Ozempic, Wegovy shortages

All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned patients may still experience "variability" filling their prescriptions.

By Ned Pagliarulo • Updated Oct. 30, 2024

An effective analytical testing strategy for viral vectors should include these 7 steps

Producing safe, effective, high-quality viral vector therapeutics depends on a robust and tailored analytical testing strategy.

Oct. 7, 2024

FDA makes end of Zepbound, Mounjaro shortage official

Removal of Lilly’s in-demand drugs from the FDA’s shortage list ramps up pressure on the companies selling compounded counterparts. 

By Kristin Jensen • Oct. 3, 2024

Lilly plans $4.5B ‘foundry’ for advanced drug manufacturing

With its latest investment, Lilly is looking toward medicines of the future and new methods to produce them.

By Kristin Jensen • Oct. 2, 2024

Sanofi readies to meet US demand for RSV antibody

With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in full supply this RSV season.

By Delilah Alvarado • Sept. 16, 2024

As Biosecure bill advances, drugmakers prepare for prospect of China pivot

While companies’ exposure to the Biosecure Act varies, drugmakers are bracing for the knock-on effects that its passage could create in the market for contract services.

By Amy Baxter • Sept. 16, 2024

Novartis builds out radiopharma production with expansion, new factory

A planned facility in California will boost Novartis’ West Coast supply chain as new uses for the company’s radioligand therapies grow.

By Kristin Jensen • Sept. 4, 2024

Regeneron confirms FDA won’t approve myeloma drug over manufacturing issues

Company executives had warned investors that a delay was likely due to issues at a facility run by a third-party manufacturer.

By Kristin Jensen • Aug. 21, 2024

Novo plans new plant as it races to meet drug demand

The new factory, which Novo is committing some $220 million to build, will supply raw materials for the company’s chronic disease medicines.

By Ned Pagliarulo • Aug. 19, 2024

Evotec, citing research spending slowdown, cuts jobs and exits gene therapy

New CEO Christian Wojczewski announced layoffs that will affect about 7% of the company’s workforce.

By Kristin Jensen • Aug. 14, 2024